Aims
We sought to determine the degree of anticoagulation reversal required to mitigate bleeding, and assess the feasibility of using pegnivacogin to prevent ischaemic events in acute coronary syndrome (ACS) patients managed with an early invasive approach. REG1 consists of pegnivacogin, an RNA aptamer selective factor IXa inhibitor, and its complementary controlling agent, anivamersen. REG1 has not been studied in invasively managed patients with ACS nor has an optimal level of reversal allowing safe sheath removal been defined.

Methods and results
Non-ST-elevation ACS patients (n = 640) with planned early cardiac catheterization via femoral access were randomized 2:1:2:2 to pegnivacogin with 25, 50, 75, or 100% anivamersen reversal or heparin. The primary endpoint was total ACUITY bleeding through 30 days. Secondary endpoints included major bleeding and the composite of death, myocardial infarction, urgent target vessel revascularization, or recurrent ischaemia. Enrolment in the 25% reversal arm was suspended after 41 patients. Enrolment was stopped after three patients experienced allergic-like reactions. Bleeding occurred in 65, 34, 35, 30, and 31% of REG1 patients with 25, 50, 75, and 100% reversal and heparin. Major bleeding occurred in 20, 11, 8, 7, and 10% of patients. Ischaemic events occurred in 3.0 and 5.7% of REG1 and heparin patients, respectively.

Conclusion
At least 50% reversal is required to allow safe sheath removal after cardiac catheterization. REG1 appears a safe strategy to anticoagulate ACS patients managed invasively and warrants further investigation in adequately powered clinical trials of patients who require short-term high-intensity anticoagulation.

Keywords
Acute coronary syndromes • Anticoagulation reversal • REG1
Introduction

Anticoagulant therapy is a cornerstone of treatment for patients with acute coronary syndromes (ACS) and is vital to the safe conduct of percutaneous coronary interventions (PCI); however, more effective antithrombotics inherently increase bleeding. Novel approaches that maintain or improve efficacy without increasing bleeding are needed.

Aptamers are single-stranded nucleic acids that form unique sequence-dependent three-dimensional structures. Aptamers are unique in that a complementary nucleic acid controlling agent can bind through Watson–Crick base pairing, alter the conformation of, and inactivate its target aptamer. As the degree of agent can bind through Watson–Crick base pairing, alter the conformation of, and inactivate its target aptamer. As the degree of agent can bind through Watson–Crick base pairing, alter the conformation of, and inactivate its target aptamer. As the degree of agent can bind through Watson–Crick base pairing, alter the conformation of, and inactivate its target aptamer. As the degree of agent can bind through Watson–Crick base pairing, alter the conformation of, and inactivate its target aptamer. As the degree of agent can bind through Watson–Crick base pairing, alter the conformation of, and inactivate its target aptamer.

The REG1 system consists of pegnivacogin, a single-stranded RNA factor IXa inhibitor, and its complementary reversal agent, anivamersen, which binds to and inactivates pegnivacogin with rapid kinetics (Figure 1). REG1 has been studied in a series of Phase 1 studies and a Phase 2a feasibility study in a small cohort (n = 22) of stable patients undergoing elective PCI. These studies demonstrated that in stable patients, pegnivacogin administered at doses of ≥0.75 mg/kg completely inhibits factor IX activity and that femoral sheath removal after 100% reversal appeared safe. The relationship between the degree of reversal and bleeding and the feasibility of using REG1 to prevent ischaemic events in patients with ACS undergoing PCI have not been established.

The RADAR (A Randomized, Partially Blinded, Multicenter, Active-Controlled, Dose-Ranging Study Assessing the Safety, Efficacy, and Pharmacodynamics of the REG1 Anticoagulation System in Patients with ACSs) trial was designed to: (1) determine the degree of anivamersen-mediated pegnivacogin reversal required to mitigate bleeding and allow early sheath removal following cardiac catheterization and (2) assess the feasibility of using the factor IX inhibitor pegnivacogin to prevent ischaemic events in patients with ACS managed with an early invasive approach. An early substudy was included to confirm near complete factor IXa inhibition with the selected pegnivacogin dose in this ACS population.

Methods

Study population and design

The design of RADAR has been previously published. RADAR was a Phase 2b, international, adaptive design, partially blinded, dose-ranging clinical trial. The protocol was approved by institutional review boards or ethics committees at each institution and all patients provided written informed consent prior to participation.

Eligibility criteria

Eligible patients were required to have a minimum of 10 min of ischaemic symptoms within 72 h of enrolment associated with (1) dynamic ST-segment changes, or (2) elevated troponin I or T or CK(MB), or (3) a history of coronary artery disease by angiography. In addition, patients had to have planned cardiac catheterization via femoral arterial access within 24 h of randomization. Major exclusion criteria included: (1) ST-segment elevation myocardial infarction (MI); (2) weight >120 kg; (3) prior use of low molecular weight heparin within 3 days or of warfarin, bivalirudin, fibrinolytic agents, or glycoprotein IIb/IIIa inhibitors within 7 days of enrolment; (4) planned use of >7 French sheaths, intraaortic balloon pumps, or other support devices; or (5) an inability to take aspirin or a thienopyridine.

Randomization and study intervention

Using a central interactive voice response system, patients were randomized 3:1 to open-label REG1 with sheath removal 10 min post-procedure or heparin with sheath removal per the standard of care. Aspirin and thienopyridine pre-treatment (clopidogrel or prasugrel) were recommended. Patients not previously treated with thienopyridines were to receive a loading dose (300 or 600 mg of clopidogrel or prasugrel, as indicated). For patients on chronic thienopyridine therapy, the administration of an additional loading dose was left to the discretion of the physician. Glycoprotein IIb/IIIa inhibitors were recommended in patients assigned to heparin. Patients randomized to REG1 received pegnivacogin (1 mg/kg over 1 min intravenously) pre-procedure and were randomized, in a 2:1:1:2 ratio, to a blinded post-procedure dose of anivamersen of 0.075, 0.2, 0.4, or 1 mg/kg to achieve 25, 50, 75, or 100% reversal, respectively. Doses were chosen based on early phase clinical studies predicting that 1 mg/kg pegnivacogin would reliably achieve near complete factor IXa inhibition and the previously defined relationship between anivamersen dose and the degree of reversal of pegnivacogin activity. Additional open-label anivamersen (1 mg/kg, a dose sufficient to completely reverse all pegnivacogin activity) could be administered if haemostasis was not achieved after 20 min. Patients who underwent coronary artery bypass graft (CABG) surgery received open-label complete reversal prior to surgery and unfractionated heparin during surgery. Patients randomized to heparin were treated using a standardized recommended dosing algorithm prior to and during catheterization and underwent femoral arterial sheath removal at a time consistent with local standard practice.
post-procedure for deep vein thrombosis prophylaxis in some locations, this was allowed per local practice in all subjects.

For all patients undergoing sheath removal using manual compression, pressure was maintained for 10 min and, if haemostasis had not been achieved, manual compression was applied for an additional 10 min. Vascular closure devices were allowed 10 min after anivamersen dosing or per the standard of care in heparin patients. An ambulance challenge was recommended within 2 h post-sheath removal in REG1 patients and per the standard of care for heparin patients.

**Endpoint definitions**

The primary endpoint was total bleeding through 30 days. Major bleeding was defined as intracranial, intracerebral bleeding or haemorrhage, access site haemorrhage requiring intervention, ≥5 cm access site haematoma, a reduction in haemoglobin levels of ≥4 g/dL without overt bleeding or ≥3 g/dL with an overt bleeding source, re-operation for bleeding, or need for any transfusion of blood products. Minor bleeding constituted any clinically evident bleeding not meeting the criteria for major bleeding.

The composite ischaemic endpoint was death, non-fatal MI, urgent target vessel revascularization, or recurrent ischaemia in the target vessel distribution through 30 days. Specific procedural complications, including abrupt or threatened coronary artery closure, distal embolization, clot formation on catheters or wires, no reflow, or any other thrombotic complication, were recorded at the time of catheterization.

All bleeding and ischaemic events were adjudicated by an independent clinical events committee blinded to the study treatment using original source documents.

**Statistical methods**

We projected a 20% absolute rate of total bleeding in the heparin arm and in the REG1 arm with 25% reversal. Based on a projected enrolment of 800 patients, the trial had 80% power to detect a 50% relative (10% absolute) reduction in bleeding in the REG1 with 100% reversal arm compared with patients in the heparin or REG1 with 25% reversal arms at an α of 0.05.

The trial employed an adaptive design. The data safety monitoring board (DSMB) reviewed efficacy (bleeding) and safety (ischaemic event) data after enrolment of 100, 200, and 400 patients. Based on pre-specified criteria, the DSMB could recommend the cessation of enrolment into lower reversal REG1 arms if excessive bleeding was observed or into the higher reversal REG1 arms for excessive ischaemic complications. Patients who would have been randomized to discontinuation of care were allowed 10 min after anivamersen dosing or per the standard of care in heparin patients. An ambulance challenge was recommended within 2 h post-sheath removal in REG1 patients and per the standard of care for heparin patients.

Outcomes

**Bleeding**

Following the DSMB review of the first 100 patients randomized, enrolment into the 25% reversal arm was stopped due to an excess of bleeding. The final patient distribution and follow-up is summarized in Figure 2.

Rates of 30-day total and major bleeding are shown in Figure 3. Bleeding was substantial in the 25% reversal arm. Other than the 25% reversal arm, rates of total bleeding were similar among the REG1 and heparin arms. Major bleeding was lower in a dose-related fashion with higher reversal strategies (P = 0.01 for trend). Open-label anivamersen to effect full reversal was used in 30.8, 5.3, 5.1, and 2.6% of the 25, 50, 75, and 100% reversal arms, respectively. There was a lower rate of total bleeding with REG1 and 100% reversal compared with REG1 and 25% reversal (Figure 3). Similar differences were observed when considering only patients enrolled in the 100% reversal arm prior to the discontinuation of the 25% reversal arm, and after adjusting for baseline differences between the 25 and 100% reversal arms. The rate of total bleeding in the 100% reversal arm was similar to the heparin arm.

When examining the incidence of bleeding from randomization through hospital discharge, anivamersen dose was directly related to both total and major bleeding (Figure 4). There was a trend towards lower bleeding in the 100% reversal arm compared with heparin (OR 0.7, 95% CI 0.4–1.1; P = 0.10), with a strong
Table 1  Demographic data of enrolled patients

<table>
<thead>
<tr>
<th></th>
<th>REG1 25%, reversal (n = 41)</th>
<th>REG1 50%, reversal (n = 117)</th>
<th>REG1 75%, reversal (n = 120)</th>
<th>REG1 100%, reversal (n = 201)</th>
<th>Total REG1 (n = 479)</th>
<th>Heparin (n = 161)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, median (25th, 75th), years</td>
<td>62.2 (51.4, 70.2)</td>
<td>63.1 (56.5, 73.2)</td>
<td>66.7 (56.8, 72.4)</td>
<td>66.1 (55.9, 72.0)</td>
<td>64.9 (55.9, 72.1)</td>
<td>62.5 (55.8, 71.2)</td>
</tr>
<tr>
<td>Range</td>
<td>37.0, 82.4</td>
<td>38.3, 86.0</td>
<td>38.5, 85.5</td>
<td>33.7, 83.5</td>
<td>33.7, 86.0</td>
<td>37.5, 83.4</td>
</tr>
<tr>
<td>Male</td>
<td>25 (61.0)</td>
<td>83 (70.9)</td>
<td>79 (65.8)</td>
<td>136 (67.7)</td>
<td>323 (67.4)</td>
<td>114 (70.8)</td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>37 (90.2)</td>
<td>112 (95.7)</td>
<td>114 (95.0)</td>
<td>191 (95.0)</td>
<td>454 (94.8)</td>
<td>152 (94.4)</td>
</tr>
<tr>
<td>Black</td>
<td>4 (9.8)</td>
<td>2 (1.7)</td>
<td>4 (3.3)</td>
<td>6 (3.0)</td>
<td>16 (3.3)</td>
<td>6 (3.7)</td>
</tr>
<tr>
<td>Other</td>
<td>0</td>
<td>3 (2.8)</td>
<td>2 (1.7)</td>
<td>4 (2.0)</td>
<td>7 (1.4)</td>
<td>3 (1.8)</td>
</tr>
<tr>
<td>Hispanic/Latino</td>
<td>2 (4.9)</td>
<td>1 (0.9)</td>
<td>2 (1.7)</td>
<td>2 (1.0)</td>
<td>7 (1.5)</td>
<td>2 (1.2)</td>
</tr>
<tr>
<td>Non-Hispanic/Latino</td>
<td>39 (95.1)</td>
<td>116 (99.1)</td>
<td>118 (98.3)</td>
<td>199 (99.0)</td>
<td>472 (98.5)</td>
<td>159 (98.8)</td>
</tr>
<tr>
<td>Past medical history</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Congestive HF</td>
<td>4 (9.8)</td>
<td>14 (12.0)</td>
<td>11 (9.2)</td>
<td>20 (10.0)</td>
<td>49 (10.2)</td>
<td>16 (9.9)</td>
</tr>
<tr>
<td>MI</td>
<td>19 (46.3)</td>
<td>64 (54.7)</td>
<td>54 (45.0)</td>
<td>95 (47.3)</td>
<td>232 (48.4)</td>
<td>75 (46.6)</td>
</tr>
<tr>
<td>Previous PCI</td>
<td>16 (39.0)</td>
<td>51 (43.6)</td>
<td>45 (37.5)</td>
<td>96 (47.8)</td>
<td>208 (43.4)</td>
<td>69 (42.9)</td>
</tr>
<tr>
<td>Previous CABG</td>
<td>5 (12.2)</td>
<td>14 (12.0)</td>
<td>19 (15.8)</td>
<td>31 (15.4)</td>
<td>69 (14.4)</td>
<td>23 (14.3)</td>
</tr>
<tr>
<td>Hypertension requiring therapy</td>
<td>29 (70.7)</td>
<td>88 (75.2)</td>
<td>91 (75.8)</td>
<td>163 (81.1)</td>
<td>371 (77.5)</td>
<td>128 (79.5)</td>
</tr>
<tr>
<td>Diabetes</td>
<td>18 (43.9)</td>
<td>47 (40.2)</td>
<td>32 (26.7)</td>
<td>60 (29.9)</td>
<td>157 (32.8)</td>
<td>42 (26.1)</td>
</tr>
<tr>
<td>Renal insufficiency</td>
<td>3 (7.3)</td>
<td>16 (13.7)</td>
<td>15 (12.5)</td>
<td>12 (6.0)</td>
<td>46 (9.6)</td>
<td>11 (6.8)</td>
</tr>
<tr>
<td>Stroke</td>
<td>5 (12.2)</td>
<td>7 (6.0)</td>
<td>6 (5.0)</td>
<td>4 (2.0)</td>
<td>22 (4.6)</td>
<td>5 (3.1)</td>
</tr>
<tr>
<td>Current tobacco use</td>
<td>15 (36.6)</td>
<td>38 (32.5)</td>
<td>24 (20.0)</td>
<td>49 (24.4)</td>
<td>126 (26.3)</td>
<td>44 (27.3)</td>
</tr>
<tr>
<td>Enrolment criteria</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New or presumably new ST-segment depression</td>
<td>11 (26.8)</td>
<td>33 (28.2)</td>
<td>30 (25.0)</td>
<td>44 (21.9)</td>
<td>118 (24.6)</td>
<td>46 (28.6)</td>
</tr>
<tr>
<td>Elevated troponin I, T, or CK-MB</td>
<td>28 (68.3)</td>
<td>67 (57.3)</td>
<td>66 (55.0)</td>
<td>91 (45.3)</td>
<td>252 (52.6)</td>
<td>88 (54.7)</td>
</tr>
<tr>
<td>History of coronary artery disease</td>
<td>19 (46.3)</td>
<td>58 (49.6)</td>
<td>52 (43.3)</td>
<td>115 (57.2)</td>
<td>244 (50.9)</td>
<td>78 (48.4)</td>
</tr>
</tbody>
</table>

Data are presented as no. (%) unless otherwise indicated. CABG, coronary artery bypass grafting; CAD, coronary artery disease; HF, heart failure; MI, myocardial infarction; PCI, percutaneous coronary intervention.

The relationship between the degree of reversal and major bleeding among REG1-treated subjects (P = 0.001).

Major (89.8%) and total bleeding (88.3%) were predominantly access site-related. One heparin-treated patient suffered an intracranial haemorrhage and major gastrointestinal bleeding occurred in three patients assigned to REG1 and one patient assigned to heparin. A total of eight (1.7%) REG1 and four (2.5%) heparin patients received non-CABG-related transfusions. There were no haemarthroses, or urinary tract or intraocular bleeding events.

Ischaemic events

The composite of 30-day death, non-fatal MI, urgent target vessel revascularization, or recurrent ischaemia in the target vessel distribution was numerically lower in patients assigned to REG1 than heparin (Figure 5). Ischaemic events were rare and evenly distributed between the various reversal arms (Table 3). The majority of ischaemic events were non-fatal periprocedural MIs. Target vessel revascularization occurred in <1% of patients and was not related to the degree of reversal. No periprocedural thrombus formation on the wire or catheters was observed in REG1-treated patients, and no patients required transition from pegnivacogin to heparin during the conduct of PCI.

Adverse events

The rates of adverse events and serious adverse events (60 and 16% in patients treated with REG1 and 55 and 11% in patients treated with heparin) were similar between REG1- and heparin-treated patients.

Three patients had allergic-like reactions shortly after pegnivacogin administration; two of these reactions were serious. The first patient had a history of allergic urticaria treated with corticosteroids and antihistamines 1 month prior to enrolment. She developed nausea, pruritus, and shortness of breath 5 min after pegnivacogin administration and was treated with corticosteroids, antihistamines, and short-term vasopressor support with resolution of all symptoms within 2 h of onset. The second patient had a history of allergy to radiographic contrast and multiple other allergies. She developed generalized urticaria without respiratory or haemodynamic changes, and was treated with steroids and antihistamines with resolution within 25 min. The
third patient had listed allergies to beta-blockers and steroids. After receiving pegnivacogin, she developed dyspnoea and cutaneous tingling. She was treated with corticosteroids, antihistamines, and haemodynamic support after developing tachycardia prompting cardioversion.

Following the third event, enrolment was put on hold. After a review of completed enrolment and aggregate event information, it was felt that the trial had sufficient data to meet its main objectives and enrolment was stopped. To determine if there were additional unrecognized allergic-like reactions, we examined the database for adverse events possibly representing unrecognized milder allergic reactions occurring within 24 h of pegnivacogin administration (Table 4). A full listing of all adverse events reported is available in the online supplementary materials at European Heart Journal online.

**Discussion**

RADAR met its primary objectives, defining that at least 50% pegnivacogin reversal is required to allow early sheath removal after cardiac catheterization via a femoral approach and suggesting that near complete inhibition of factor IXa with pegnivacogin, followed by anivamersen-mediated reversal, may provide a strategy that permits effective periprocedural anticoagulation without increased bleeding despite immediate post-procedure sheath removal.

**Pharmacodynamic dose verification**

Factor IXa activity and thrombin generation are heightened among patients with ACS, and anticoagulant dosing from stable patients may not translate to more acute settings. We therefore felt it important to verify that dosing based on early phase studies resulted in near complete factor IXa inhibition in RADAR. Our pharmacodynamic substudy demonstrated that pegnivacogin at 1 mg/kg achieves near complete and stable inhibition of factor IXa activity in patients with ACS undergoing cardiac catheterization.

**Bleeding**

The primary objective of RADAR was to define the degree of pegnivacogin reversal required to allow prompt femoral sheath removal at the conclusion of cardiac catheterization. RADAR demonstrated that 25% reversal of pegnivacogin anticoagulation is inadequate, while an
anivamersen dose that achieves at least 50% pegnivacogin reversal is sufficient to allow early removal of femoral sheaths with bleeding rates that appear similar to those observed with heparin.

Assessment of bleeding between REG1- and heparin-treated patients may have been biased by the open-label assignment of these groups. The incidence of minor bleeding between discharge and 30-day follow-up was higher in REG1-treated patients, and did not vary with reversal strategy. Since patients who were randomized to high levels of reversal had normalized coagulation parameters prior to discharge, there may have been ascertainment bias with greater attention to the identification of minor bleeding in patients treated with REG1 compared with those receiving heparin. Major bleeding, which may be less subject to ascertainment bias, appeared more directly related to the dose of anivamersen and was numerically lower in the 100% reversal group compared with heparin. The rate of use of open-label anivamersen to normalize coagulation parameters mirrors these results. These results, however, require confirmation in a larger and preferably blinded clinical trial.

Ischaemic events

Given the availability of reversal with anivamersen, we chose a dose of pegnivacogin that would reliably achieve near complete inhibition of factor IXa. High-dose direct factor Xa inhibition has resulted in improved efficacy but with dose-limiting bleeding.13 RADAR suggests that a strategy of high-level anticoagulation followed by controlled reversal might be attractive in patients with ACS undergoing invasive management. A theoretical concern is that immediate, complete reversal of anticoagulation might result in an increased risk of acute thrombotic complications. Although the number of events is low, we did not observe any increase in acute (<24 h) or short-term (30 days) thrombotic events with higher levels of reversal.

Table 3  Ischaemic events by treatment arm

<table>
<thead>
<tr>
<th></th>
<th>REG1 25%</th>
<th>REG1 50%</th>
<th>REG1 75%</th>
<th>REG1 100%</th>
<th>REG1 overall</th>
<th>Heparin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Composite</td>
<td>3 (7.5)</td>
<td>1 (0.9)</td>
<td>5 (4.2)</td>
<td>5 (2.6)</td>
<td>14 (3.0)</td>
<td>9 (5.7)</td>
</tr>
<tr>
<td>Death</td>
<td>0</td>
<td>0</td>
<td>1 (0.8)</td>
<td>0</td>
<td>1 (0.2)</td>
<td>1 (0.6)</td>
</tr>
<tr>
<td>MI</td>
<td>3 (7.5)</td>
<td>1 (0.9)</td>
<td>4 (3.4)</td>
<td>4 (2.1)</td>
<td>12 (2.6)</td>
<td>7 (4.5)</td>
</tr>
<tr>
<td>Urgent TVR</td>
<td>1 (2.6)</td>
<td>0</td>
<td>1 (0.8)</td>
<td>1 (0.5)</td>
<td>3 (0.6)</td>
<td>1 (0.6)</td>
</tr>
</tbody>
</table>

Values presented as no. (%). There were no recurrent ischaemic events. MI, myocardial infarction; TVR, target vessel revascularization.

Factor IXa inhibition

Factor IXa is a theoretically attractive target but has not been validated as a clinically effective target for therapeutic
anticoagulation.\textsuperscript{14} Factor IXa is the proximal driver of thrombin generation\textsuperscript{15} and is directly activated by foreign materials, and increased factor IX activity has been associated with a higher incidence of clinical thrombotic events.\textsuperscript{11,12} In addition, factor IX concentrations are lower and less variable than those of factor X or thrombin, making consistent high-level target inhibition theoretically more achievable. The results of this study suggest that factor IXa inhibition does represent a viable and potentially effective strategy for anticoagulation. There were no cases of intra-procedural thrombosis, clots formed on equipment, or ‘bail-out’ use of heparin that for anticoagulation. There were no cases of intra-procedural thrombosis, clots formed on equipment, or ‘bail-out’ use of heparin that suggested inadequate intra-procedural anticoagulation.\textsuperscript{16}:

### Table 4 Incidence of allergic-like adverse events within 24 h of drug administration

<table>
<thead>
<tr>
<th>Adverse events</th>
<th>REG1 (n = 465)</th>
<th>Heparin (n = 163)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hives</td>
<td>0.2</td>
<td>—</td>
</tr>
<tr>
<td>Hypotension</td>
<td>2.4</td>
<td>1.9</td>
</tr>
<tr>
<td>Rash</td>
<td>—</td>
<td>0.7</td>
</tr>
<tr>
<td>Dyspnoea</td>
<td>0.9</td>
<td>—</td>
</tr>
</tbody>
</table>

Values presented as percentages.

Timing of sheath removal

By design, REG1 patients underwent prompt sheath removal post-procedure, while subjects randomized to heparin had their sheaths removed according to the local standard of care. This resulted in a substantial difference in the time from the end of the procedure to sheath removal between these strategies. Delayed sheath removal has been repeatedly shown to be associated with bleeding.\textsuperscript{17–19} The use of vascular closure devices reduces the time to sheath removal; however, they have not consistently been shown to reduce bleeding complications and may increase vascular complications.\textsuperscript{20–22} While radial access also allows early sheath removal, it results in greater patient and operator radiation exposure,\textsuperscript{23} may not improve cardiac outcomes,\textsuperscript{24} and is not compatible with procedures requiring larger sheath sizes.

Allergic-like reactions

Ribonucleic acid aptamers are inherently non-immunogenic and extensive analysis in pre-clinical models and early clinical trials\textsuperscript{5–7} has failed to demonstrate aptamer-mediated complement activation. The nucleic acid component of pegnivacogin is connected to a 40 kDa polyethylene glycol (PEG) chain to increase its stability and prolong its half-life. While antibodies to PEG have been reported,\textsuperscript{25–27} their incidence is low and first exposure reactions to PEG are uncommon.

Whether the three events observed in RADAR represent an inherent immunogenic property of pegnivacogin, reactions due to patient-specific factors, a random clustering of otherwise rare events, or a manifestation of degradation or contamination in the study drug is under investigation. Investigation of the study drug has not revealed product degradation, lot specificity, or other manufacturing issues as a cause. Each reaction occurred soon (<30 min) after pegnivacogin administration and prior to the administration of contrast. Potential mechanisms of such reactions might include direct complement activation, mast cell activation, or antibody-mediated mechanisms. Extensive primate studies as well as monitoring performed throughout Phase 1 (n = 161) revealed no evidence of complement activation. While mast cell activation has not been specifically evaluated, there were no clinical signs suggestive of pegnivacogin-mediated mast cell activation.

Given the first exposure nature of the observed reactions, antibody-mediated mechanisms would require cross-reactivity between pegnivacogin and a pre-formed antibody. The modifications to and size of the oligonucleotide make first-exposure reactions unlikely. Prior exposure to the PEG component could be a possible culprit. In this regard, the prior history of allergy in each of the subjects might be relevant. If and when pegnivacogin is studied in subsequent clinical trials, systematic screening for allergy history, routine collection of blood samples for analysis, initial enrolment of lower risk patients, and appropriate education and management plans for potential allergic reactions should be considered.

Limitations

The partially open-label design makes comparisons between REG1 and heparin subject to potential bias; however, the primary comparison of bleeding among REG-1 reversal strategies was blinded. As a Phase 2 trial, RADAR was not powered to determine the safety or efficacy of REG1 compared with other anticoagulant strategies. We used a relatively liberal definition of major bleeding to increase our ability to detect differences among groups. Similar definitions have been used in other Phase 2\textsuperscript{28} and Phase 3 studies,\textsuperscript{29,30} and the use of a stricter definition excluding haemotoma as a major bleeding criterion did not affect the results. Finally post-randomization decisions, including administration of open-label heparin, may have both influenced and been influenced by post-randomization bleeding and ischaemic events.

Conclusion

At least 50% anivamersen-mediated reversal of pegnivacogin is required to effectively mitigate bleeding after early femoral sheath removal in invasively managed patients with ACS. Adequately powered randomized clinical trials are warranted to determine the safety and efficacy of factor IXa inhibition with REG1 compared with other anticoagulant strategies in patients who require high-intensity, short-term anticoagulation.

Supplementary material

Supplementary material is available at European Heart Journal online.

Acknowledgements

We acknowledge all the investigators and research staff, as well as the patients who contributed to RADAR. In addition, we thank Elizabeth Cook for her editorial assistance with the manuscript.
Funding
The RADAR trial was supported by Regado Biosciences, Inc.

Conflict of interest: T.J.P. receives research salary support through Duke Clinical Research Institute from Regado Biosciences and has received compensation for attending Regado Bioscience’s Medical Advisory Board meetings. J.P.V. receives research salary support through Duke Clinical Research Institute from Regado Biosciences. L.H.A. receives research salary support through Duke Clinical Research Institute from Regado Biosciences and has received compensation for service on Regado Biosciences’ Medical Advisory Board. J.H.A. receives research salary support through Duke Clinical Research Institute from Regado Biosciences and has received compensation for service on Regado Biosciences’ Medical Advisory Board. J.D.K., C.B., C.E.B., I.H.C., A.R., M.N., and N.D. have no conflicts to declare. Duke University’s institutional conflict of interest is included in online supplementary materials at European Heart Journal online.

Appendix

Steering Committee: John H. Alexander (Chair), Duke Clinical Research Institute, Durham, NC, USA; Richard Becker, Duke Clinical Research Institute, Durham, NC, USA; Christoph Bode, MD, University of Freiberg, Freiberg, Germany; Christopher E. Buller, MD, Hamilton General Hospital, Hamilton, Ontario, Canada; Mauricio G. Cohen, MD, University of Miami Miller School of Medicine, Miami, FL, USA; Jan H. Cornel, MD, Medisch Centrum Alkmaar, Alkmaar, the Netherlands; Jaroslav D. Kaspzrak, MD, Medical University of Lodz, Łódź, Poland; Roxana Mehran, MD, Mount Sinai School of Medicine, New York, NY, USA; Gilles Montalescot, MD, Institut de Cardiologie, Pitié-Salpêtrière Hospital, Paris, France; Thomas J. Povsic, Duke Clinical Research Institute, Durham, NC, USA; Steven L. Zelenkofske, DO, Regado Biosciences, Basking Ridge, NJ, USA.

Data Safety Monitoring Board: Ronald Waksman, MD, Washington Heart Center (chair); Stefan James, MD, Uppsala Clinical Research Center; Jack Ansell, MD, Lenox Hill Hospital; Vic Hasselblad, PhD, Duke Clinical Research Institute; and Rebecca Torguson, MPH, Washington Heart Center.

References
1. Becker RC, Rusconi C, Sullenger B. Nucleic acid aptamers in therapeutic anticoa-
2. Becker RC, Povsic TJ, Cohen MG, Rusconi CP, Sullenger BA. Nucleic acid apta-
3. Povsic TJ, Sullenger B, Zelenkofske S, Rusconi C, Becker R. Translating nucleic acid apta-
7. Chan MY, Rusconi CP, Alexander JH, Harrington RA, Becker RC. A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-
8. Cohen MG, Purdy DA, Rossi JS, Grinfeld LR, Myles SK, Aberle LH, Greenbaum AB, Fry E, Chan MY, Tonkens RM, Zelenkofske S, Alexander JH, Harrington RA, Rusconi CP, Becker RC. First clinical application of an actively re-
versible direct factor IXa inhibitor as an anticoagulation strategy in patients under-
12. Miller GJ, Ireland HA, Cooper JA, Bauer KA, Morrissey JH, Humphries SE, Eikelboom JW. Relationship between markers of activated coagulation, their correl-
16. The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Inves-
tigators. Comparison of fondaparinux and enoxaparin in acute coronary syn-
18. Galli R, Steinhubl SR, White HD, Montalescot G. Impact of anticoagulation regi-
mens on sheath management and bleeding in patients undergoing elective percu-
21. Valitkus PT. A meta-analysis of percutaneous vascular closure devices after diag-
Transcoronary septal ablation in hypertrophic obstructive cardiomyopathy by embolizing microspheres†

Boris Dickmann†*, Theodor Baars†, Gerd Heusch†, and Raimund Erbel†

†Department of Cardiology, West German Heart Center Essen, Essen, Germany and ‡Institute for Pathophysiology, University of Duisburg-Essen, Essen, Germany

* Corresponding author. Tel: +49 201 72384883. Fax: +49 201 7235401. Email: boris.dickmann@uk-essen.de

† This article is dedicated to the late Thomas Konorza.

A 62-year-old male patient with hypertrophic obstructive cardiomyopathy (HOCM) under treatment with β-blockers and calcium antagonists was admitted for dyspnoea (NYHA III). Heart rate was 45 b.p.m. (Panel A) and echocardiography revealed left ventricular outflow tract obstruction (estimated pressure gradient at rest 70 mmHg; after exercise 89 mmHg) and systolic anterior motion of the mitral leaflet. Cardiac magnetic resonance imaging confirmed HOCM (Panel B). A peak gradient between the left ventricle and the aorta of 18 mmHg was augmented to 113 mmHg in the post-extrasystolic beat (Brockenbrough–Braunwald–Morrow sign, Panel C). Transcoronary septal ablation was performed by microspheres embolization (Embozene®, CeloNova, Newman, USA; diameter: 75 μm) (Panel D). The first septal branch was occluded for 10 min (Panel E) and a suspension of 1.4 mio microspheres diluted in 5 ml contrast agent was slowly injected distally. Postprocedurally, the pressure gradient was decreased and the Brockenbrough–Braunwald–Morrow sign absent (Panel F). No AV, or bundle branch block, but ST-elevation in V1–V4 (Panel G) was seen. Troponin I peaked at 93 ng/mL, creatine kinase at 2851 U/I, and myoglobin at 486 μg/L. Magnetic resonance imaging revealed new patchy contrast enhancement of the basal- and mid-ventricular septum (Panels H and I). Left ventricular ejection fraction remained largely unchanged (66 vs. 73%). On echocardiography the stress-induced pressure gradient was reduced from 89 to 23 mmHg. After 5 days, the patient was discharged.

The conceptual advantage of microspheres over alcohol for septal ablation is the confinement of microspheres to the vasculature and thus of necrosis to the ischaemic perfusion territory; this poses a lesser threat to the left bundle branch which is at least partially served by diffusion from the left ventricular cavity.